company background image
PRTK

Paratek Pharmaceuticals NasdaqGM:PRTK Stock Report

Last Price

US$2.57

Market Cap

US$141.0m

7D

12.2%

1Y

-47.4%

Updated

01 Oct, 2022

Data

Company Financials +
PRTK fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health2/6
Dividends0/6

PRTK Stock Overview

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use.

Paratek Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Paratek Pharmaceuticals
Historical stock prices
Current Share PriceUS$2.57
52 Week HighUS$5.41
52 Week LowUS$1.60
Beta1.48
1 Month Change1.98%
3 Month Change31.12%
1 Year Change-47.44%
3 Year Change-34.44%
5 Year Change-89.88%
Change since IPO-83.94%

Recent News & Updates

Aug 24

Paratek Pharmaceuticals: Patience Is Wearing Thin

Summary Today, we put Paratek Pharmaceuticals in the spotlight for the first time since the early fall of last year. Paratek is advancing its flagship product NUZYRA nicely, but shareholders have not been rewarded to this point in time even as the shares have strong analyst support. What lies ahead for Paratek? An investment analysis follows in the paragraphs below. If you must speak ill of another, do not speak it, write it in the sand near the water's edge. ― Napoleon Hill Today, we are circling back on Paratek Pharmaceuticals (PRTK) for the first time since we posted this piece on this small antibiotic concern back in October of last year. Even as the company has demonstrated solid revenue growth, shareholders have not been rewarded in this name over the past year and patience is starting to wear thin. We update our investment thesis around Paratek Pharmaceuticals via the analysis below. Seeking Alpha Company Overview Paratek Pharmaceuticals is a Boston based antibiotic concern. The company's primary asset is NUZYRA. This is a once-daily oral and intravenous broad-spectrum antibiotic approved for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens. The stock sells for around $2.75 a share and sports an approximate market cap of just under $150 million. August Company Presentation The company has some earlier stage candidates in its pipeline. None of them of note to this analysis given they are early in development. The company is advancing NUZYRA in Phase 2 development for Non-Tuberculous Mycobacteria or NTM for which it has Orphan Drug and Fast Track designations from the FDA. August Company Presentation Second Quarter Results On August 3rd, the company posted second quarter numbers. Paratek posted a GAAP loss of 33 cents a share, just a tad above the consensus. Net revenue for the second quarter of 2022 was $29.6 million. This compares to $19.6 million in 2Q2021 when excluding the first procurement of NUZYRA under the BARDA contract of $37.9 million (more detail on that contract in the last section of this article). August Company Presentation The $29.6 million in sales for the quarter included $25.1 million of revenues from NUZYRA's core commercial business. This was up from $14.9 million from the same period a year ago. The company also booked $4 million in sales from the BARDA contract and $600,000 in royalty revenue from SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. August Company Presentation Analyst Commentary & Balance Sheet Only three analyst firms have chimed in around Paratek so far in 2022. On February 10th, WBB Securities upgraded the shares to a Strong Buy with a $11 price target as the analyst there believes 'Nuzyra is a critically important antibiotic that has anchored the franchise'. This month BTIG ($30 price target) and H.C. Wainwright ($20 price target) both maintained their Buy ratings on the stock. Just under 10% of the outstanding float is currently held short. Four insiders sold just over $300,000 worth of shares collectively in August. That has been the only insider activity in the equity so far in 2022. The company ended the first half of this year with nearly $70 million in cash and marketable securities on its balance sheet. Management stated within its second quarter earnings press release that: Based upon the company's current operating plan, Paratek anticipates its existing cash, cash equivalents and marketable securities of $69.4 million as of June 30, 2022, provides for a cash runway through the end of 2023 with a pathway to cash flow break-even. August Company Presentation Verdict The current analyst consensus has the company losing a bit over 80 cents a share in FY2022 as revenues rise in the mid teens to some $150 million. Projections from three analyst firms that have provided estimates for FY2023 are in wide range both for earnings (A 42 cent a share loss to profits of $1.37 a share) and revenues ($195 million to $315 million).

Aug 03

Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M

Paratek Pharmaceuticals press release (NASDAQ:PRTK): Q2 GAAP EPS of -$0.33 beats by $0.01. Revenue of $29.6M (-48.5% Y/Y) beats by $0.42M. Based upon the company’s current operating plan, Paratek anticipates its existing cash, cash equivalents and marketable securities of $69.4M as of June 30, 2022, provides for a cash runway through the end of 2023 with a pathway to cash flow break-even.

Shareholder Returns

PRTKUS PharmaceuticalsUS Market
7D12.2%-0.04%-2.5%
1Y-47.4%3.2%-23.2%

Return vs Industry: PRTK underperformed the US Pharmaceuticals industry which returned 3.2% over the past year.

Return vs Market: PRTK underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is PRTK's price volatile compared to industry and market?
PRTK volatility
PRTK Average Weekly Movement10.7%
Pharmaceuticals Industry Average Movement11.2%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.8%

Stable Share Price: PRTK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: PRTK's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996208Evan Lohhttps://paratekpharma.com

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd.

Paratek Pharmaceuticals Fundamentals Summary

How do Paratek Pharmaceuticals's earnings and revenue compare to its market cap?
PRTK fundamental statistics
Market CapUS$141.00m
Earnings (TTM)-US$85.98m
Revenue (TTM)US$110.74m

1.3x

P/S Ratio

-1.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PRTK income statement (TTM)
RevenueUS$110.74m
Cost of RevenueUS$50.74m
Gross ProfitUS$60.00m
Other ExpensesUS$145.98m
Earnings-US$85.98m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.57
Gross Margin54.18%
Net Profit Margin-77.64%
Debt/Equity Ratio-172.2%

How did PRTK perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is PRTK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PRTK?

Other financial metrics that can be useful for relative valuation.

PRTK key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3x
Enterprise Value/EBITDA-4.9x
PEG Ration/a

Price to Sales Ratio vs Peers

How does PRTK's PS Ratio compare to its peers?

PRTK PS Ratio vs Peers
The above table shows the PS ratio for PRTK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average7.5x
MRMD MariMed
1.1x13.7%US$147.0m
SCYX SCYNEXIS
25.1x63.2%US$78.4m
PRPH ProPhase Labs
1.4x-24.7%US$180.6m
XERS Xeris Biopharma Holdings
2.7x27.7%US$212.1m
PRTK Paratek Pharmaceuticals
1.3x26.8%US$141.0m

Price-To-Sales vs Peers: PRTK is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (7.5x).


Price to Earnings Ratio vs Industry

How does PRTK's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Sales vs Industry: PRTK is good value based on its Price-To-Sales Ratio (1.3x) compared to the US Pharmaceuticals industry average (2.9x)


Price to Sales Ratio vs Fair Ratio

What is PRTK's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PRTK PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.3x
Fair PS Ratio4.3x

Price-To-Sales vs Fair Ratio: PRTK is good value based on its Price-To-Sales Ratio (1.3x) compared to the estimated Fair Price-To-Sales Ratio (4.3x).


Share Price vs Fair Value

What is the Fair Price of PRTK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PRTK's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PRTK's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Paratek Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


62.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PRTK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: PRTK is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PRTK is expected to become profitable in the next 3 years.

Revenue vs Market: PRTK's revenue (26.8% per year) is forecast to grow faster than the US market (7.7% per year).

High Growth Revenue: PRTK's revenue (26.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PRTK's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Paratek Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


8.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PRTK is currently unprofitable.

Growing Profit Margin: PRTK is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PRTK is unprofitable, but has reduced losses over the past 5 years at a rate of 8% per year.

Accelerating Growth: Unable to compare PRTK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PRTK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).


Return on Equity

High ROE: PRTK's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Discover strong past performing companies

Financial Health

How is Paratek Pharmaceuticals's financial position?

Financial Health Score

2/6

Financial Health Score 2/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: PRTK has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: PRTK has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: PRTK has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: PRTK's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PRTK has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PRTK has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 3.5% each year.


Discover healthy companies

Dividend

What is Paratek Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Paratek Pharmaceuticals Dividend Yield vs Market
How does Paratek Pharmaceuticals dividend yield compare to the market?
SegmentDividend Yield
Company (Paratek Pharmaceuticals)n/a
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Pharmaceuticals)2.6%
Analyst forecast in 3 Years (Paratek Pharmaceuticals)n/a

Notable Dividend: Unable to evaluate PRTK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PRTK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PRTK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PRTK's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PRTK has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Evan Loh (63 yo)

10.25yrs

Tenure

US$3,612,490

Compensation

Dr. Evan Loh, M.D., FACC, FAHA, has been the Chief Executive Officer of Paratek Pharmaceuticals, Inc. since June 25, 2019. Dr. Loh served as Independent Director at Windtree Therapeutics, Inc. since Februa...


CEO Compensation Analysis

Evan Loh's Compensation vs Paratek Pharmaceuticals Earnings
How has Evan Loh's remuneration changed compared to Paratek Pharmaceuticals's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$86m

Mar 31 2022n/an/a

-US$59m

Dec 31 2021US$4mUS$600k

-US$59m

Sep 30 2021n/an/a

-US$52m

Jun 30 2021n/an/a

-US$54m

Mar 31 2021n/an/a

-US$87m

Dec 31 2020US$2mUS$575k

-US$97m

Sep 30 2020n/an/a

-US$99m

Jun 30 2020n/an/a

-US$111m

Mar 31 2020n/an/a

-US$121m

Dec 31 2019US$2mUS$520k

-US$129m

Sep 30 2019n/an/a

-US$124m

Jun 30 2019n/an/a

-US$124m

Mar 31 2019n/an/a

-US$120m

Dec 31 2018US$2mUS$480k

-US$112m

Sep 30 2018n/an/a

-US$111m

Jun 30 2018n/an/a

-US$101m

Mar 31 2018n/an/a

-US$89m

Dec 31 2017US$3mUS$450k

-US$89m

Sep 30 2017n/an/a

-US$94m

Jun 30 2017n/an/a

-US$96m

Mar 31 2017n/an/a

-US$108m

Dec 31 2016US$1mUS$415k

-US$112m

Sep 30 2016n/an/a

-US$106m

Jun 30 2016n/an/a

-US$106m

Mar 31 2016n/an/a

-US$91m

Dec 31 2015US$2mUS$360k

-US$71m

Compensation vs Market: Evan's total compensation ($USD3.61M) is above average for companies of similar size in the US market ($USD774.31K).

Compensation vs Earnings: Evan's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: PRTK's management team is considered experienced (3.5 years average tenure).


Board Members

Experienced Board: PRTK's board of directors are considered experienced (7.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of PRTK?
Owner TypeNumber of SharesOwnership Percentage
VC/PE Firms3,887,1727.1%
Individual Insiders8,114,04314.8%
Institutions20,759,38137.8%
General Public22,101,90640.3%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.4%.


Top Shareholders

Top 25 shareholders own 52.86% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
7.09%
Aigh Capital Management, LLC
3,887,172$10.0m14.76%3.97%
5.85%
Laurence Lytton
3,210,552$8.3m0%no data
4.51%
James Dondero
2,474,060$6.4m0%no data
3.68%
The Vanguard Group, Inc.
2,019,686$5.2m-11.37%no data
3.59%
Omega Fund Management, LLC
1,971,241$5.1m0%1.31%
3.55%
Medical Strategy GmbH, Asset Management Arm
1,948,576$5.0m4.16%0.32%
3.19%
General American Investors Company, Inc.
1,752,470$4.5m21.01%0.41%
3.16%
Rock Springs Capital Management LP
1,734,037$4.5m0.43%0.12%
2.84%
Bruce & Co Inc
1,557,312$4.0m0%0.99%
1.9%
Abingworth LLP
1,041,131$2.7m0%0.83%
1.58%
BlackRock, Inc.
869,224$2.2m-70.44%no data
1.48%
Fortress Investment Group LLC
809,651$2.1m-14.07%0.14%
1.41%
Evan Loh
770,992$2.0m16.32%no data
1.2%
Michael Bigham
661,062$1.7m20.96%no data
0.92%
Millennium Management LLC
504,221$1.3m218.78%no data
0.9%
Telemetry Investments, L.L.C.
495,000$1.3m36.36%2.15%
0.89%
1492 Capital Management, LLC
489,376$1.3m-4.01%0.87%
0.88%
Pictet Asset Management Limited
481,827$1.2m13.03%no data
0.8%
Geode Capital Management, LLC
436,319$1.1m-45.87%no data
0.72%
Adam Woodrow
392,920$1.0m22.28%no data
0.64%
CM Management, LLC
350,000$899.5k0%0.93%
0.54%
Renaissance Technologies LLC
296,676$762.5k71.07%no data
0.54%
Trellus Management Company, LLC
295,000$758.2k0%1.15%
0.52%
Brown Brothers Harriman & Co., Asset Management Arm
287,902$739.9k0%0.01%
0.48%
William Haskel
261,933$673.2k10.68%no data

Company Information

Paratek Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Paratek Pharmaceuticals, Inc.
  • Ticker: PRTK
  • Exchange: NasdaqGM
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$140.997m
  • Shares outstanding: 54.86m
  • Website: https://paratekpharma.com

Number of Employees


Location

  • Paratek Pharmaceuticals, Inc.
  • 75 Park Plaza
  • 4th Floor
  • Boston
  • Massachusetts
  • 2116
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PRTKNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDOct 2014
N4CNDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2014

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/01 00:00
End of Day Share Price2022/09/30 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.